

1 UNITED STATES DISTRICT COURT
2 SOUTHERN DISTRICT OF WEST VIRGINIA
3 AT CHARLESTON
4

5 -----)
6 IN RE: ETHICON, INC., PELVIC)Master File
7 REPAIR SYSTEM PRODUCTS)No. 2:12-MD-02327
8 LIABILITY LITIGATION)MDL 2327
9 -----)
10 THIS DOCUMENT RELATES TO)JOSEPH R. GOODWIN
11 CAROLYN LEWIS, et al. v.)U.S. DISTRICT JUDGE
12 ETHICON, INC.)
13 Case No. 2:12-CV-04301)
14 -----)

15
16 The deposition of BRUCE A. ROSENZWEIG,
17 M.D., called for examination, taken pursuant to the
18 Federal Rules of Civil Procedure of the United
19 States District Courts pertaining to the taking of
20 depositions, taken before JULIANA F. ZAJICEK, CSR
21 No. 84-2604, a Certified Shorthand Reporter of said
22 State of Illinois, at the offices of Wexler
23 Wallace, Suite 3300, 55 West Monroe Street,
24 Chicago, Illinois, on November 4, 2013, at 9:00 a.m.
25

1 APPEARANCES:

2 APPEARED ON BEHALF OF THE PLAINTIFFS:

3 WAGSTAFF & CARTMELL LLP
4 4740 Grand Avenue, Suite 300
5 Kansas City, Missouri 64112
6 816-701-1100

7 BY: THOMAS P. CARTMELL, ESQ.
8 tcartmell@wcllp.com;
9 JEFFREY M. KUNTZ, ESQ.
10 jkuntz@wcllp.com

11

-and-

12

13 MATTHEWS & ASSOCIATES
14 2905 Sackett Street
15 Houston, Texas 77098
16 713-522-5250

17 BY: DAVID P. MATTHEWS
18 dmatthews@dpmlawfirm.com

19 -and-

20 AYLSTOCK, WITKIN, KREIS & OVERHOLTZ, PLLC
21 17 East Main Street, Suite 200
22 Pensacola, Florida 32502
23 850-202-1010

24 BY: RENEE BAGGETT, ESQ. (Telephonically)
25 rbaggett@awkolaw.com

26

27 APPEARED TELEPHONICALLY ON BEHALF OF THE PLAINTIFF
28 CAROLYN LEWIS:

29 FREESE & GOSS PLLC
30 Regions Harbert Plaza 1901
31 6th Avenue North
32 Birmingham, Alabama 35203
33 205-871-4144

34 BY: CALLE M. MENDENHALL, ESQ.
35 calle@freeseandgoss.com

36

37

38

39

1 APPEARED ON BEHALF OF THE DEFENDANTS:

2 BUTLER, SNOW, O'MARA, STEVENS & CANNADA, PLLC
1020 Highland Colony Parkway, Suite 1400
3 Ridgeland, Mississippi 39158-6010
601-948-5711

4 BY: CHRISTY D. JONES, ESQ.

christy.jones@butlersnow.com;

5 PAUL S. ROSENBLATT, ESQ.

paul.rosenblatt@butlersnow.com

6

7

8

9

10 REPORTED BY: JULIANA F. ZAJICEK, CSR No. 84-2604.

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1 (WHEREUPON, the witness was duly
2 sworn.)

3 BRUCE A. ROSENZWEIG, M.D.,
4 called as a witness herein, having been first duly
5 sworn, was examined and testified as follows:

6 EXAMINATION

7 BY MS. JONES:

8 Q. Doctor, would you state your name and
9 address for us please, sir?

10 A. Bruce Alan Rosenzweig. My professional
11 address is 1725 West Harrison Street, Suite 358,
12 Chicago, Illinois 60612.

13 Q. And, Doctor, you are an
14 obstetrician/gynecologist by training?

15 A. That is correct.

16 Q. And do I understand correctly that you
17 are in private practice, in the private practice of
18 medicine here in Chicago now?

19 A. That is correct.

20 Q. How long have you been in private
21 practice?

22 A. Well, I -- I started here in Chicago at
23 the University of Illinois in 1998, I moved to
24 Mercy Hospital where I was in more of a private
25 practice than an academic practice, then I moved

1 time and the time that you started working in this
2 litigation?

3 A. I -- I know I looked at a lot of patent
4 documents. I don't remember specifically if the
5 patent infringement case I was working on I saw
6 510(k) documents. So, I don't want to say yes at
7 that point, which was also about six or seven years
8 ago.

9 Q. Have you ever prepared clinical expert
10 reports?

11 A. No, I have not.

12 Q. Have you ever prepared design history
13 files?

14 A. No, I have not.

15 Q. Have you ever prepared DFMEAs?

16 A. No, I have not.

17 Q. Have you ever prepared IFUs?

18 A. Well, I did work with Gish Biomedical to
19 get the information that they needed to put in the
20 amniocentesis catheter IFU.

21 Q. Did you actually draft the IFU?

22 A. No, I did not. I worked as a consultant
23 on that.

24 Q. Have you ever drafted an IFU?

25 A. No, I have not.

1 Q. Have you ever drafted a patient
2 brochure?

3 A. I worked on the amnioinfusion catheter
4 brochures, yes.

5 Q. Other than your working as a consultant
6 with Gish on the IFU and patient brochure on the
7 IFU, have you ever had any other experience either
8 as a consultant or drafting an IFU or patient
9 brochure?

10 A. Yes. I was on EMPI's scientific
11 advisory committee in the mid-'90s and I know we
12 worked on various documents like that. I can't --

13 Q. You were on whose scientific advisory
14 committee?

15 A. EMPI. It is a company in Minnesota that
16 makes an electrical stimulator for the treatment of
17 stress incontinence and urge incontinence.

18 Q. And so your role there was?

19 A. An adviser to -- at that point they were
20 working on doing a prospective randomized
21 controlled trial because the insurance companies
22 were looking at this technique as experimental, and
23 so they needed to get some data in the literature
24 to show that it wasn't experimental.

25 Q. Have you ever prepared any risk

1 management reports?

2 A. No, ma'am. Well, risk management as far
3 as medical -- medical products, right?

4 Q. Right.

5 A. Okay. Good.

6 Q. Not in terms of your hospital --

7 A. Patients, doctors, right.

8 Q. -- services and patients and all of
9 that.

10 Have you ever been an employee or
11 consultant to the FDA?

12 A. No, I have not.

13 Q. Have you ever served on an FDA advisory
14 committee meeting?

15 A. No, I have not.

16 Q. Have you ever corresponded with the FDA
17 with respect to your opinions on anything about a
18 medical device?

19 A. No, I have not.

20 Q. Have you ever shared with the FDA any of
21 your opinions that you have included within your
22 reports marked as Exhibits 2 and 3 here?

23 A. No, I have not.

24 Q. Have you ever published these opinions
25 in any other form other than in this report marked

1 as Exhibit 2 and 3?

2 A. I think there is some of the I'll call
3 it factual information in a presentation that I
4 gave this year about polypropylene degradation and
5 stuff like that, but that would be the only thing.

6 Q. That would be in one of the --

7 A. Slide decks, yes.

8 Q. -- slide decks?

9 A. Yes.

10 Q. Again, we'll come back to those --

11 A. Excellent.

12 Q. -- in just a second.

13 You don't have any background in polymer
14 chemistry, do you?

15 A. No, ma'am.

16 Q. You don't consider yourself to be a
17 biomaterial specialist?

18 A. I have not studied biomaterials, nor do
19 I have an advanced degree in biomaterials.

20 Q. And I take it it's true that you've
21 never done any bench research or lab research with
22 respect to polypropylene?

23 A. Not to polypropylene.

24 Q. Am I correct that you have never advised
25 the FDA of any of your opinions that you've

1 device report to either the FDA or to Ethicon?

2 A. Yes. I filled out the paperwork for
3 those.

4 Q. And this was in when?

5 A. 2004, 2005, 2006.

6 Q. On how many occasions?

7 A. I'm going to say at the most five.

8 Q. Were these implants that you had
9 implanted?

10 A. There was one case that I remember that
11 I implanted that had an erosion, and I'm pretty
12 sure I filled out the paperwork with the rep on
13 that case, but the other ones were ones that were
14 sent to me.

15 Q. All right. Now, my initial question to
16 you was degradation --

17 A. That is correct.

18 Q. -- not erosion. So my -- let me go back
19 and make sure that we are on the same page.

20 Did you report to anyone a finding of
21 erosion -- of degradation in 2004 or 2005?

22 A. No, ma'am.

23 Q. Have you ever reported that to anyone?

24 A. No, ma'am.

25 Q. Have you ever done any type of

1 pathological analysis on a removed TVT or implant?

2 A. Myself?

3 Q. Yes, sir.

4 A. No, ma'am.

5 Q. Have you ever ordered that one be done?

6 A. I send the explants that I do down to
7 pathology, so I guess that would be considered
8 ordering.

9 Q. And they would do whatever their normal
10 pathological process or procedure is in terms and
11 then those records would just be included within
12 the medical records?

13 A. That is correct.

14 Q. Other than that, have you been engaged
15 in any type of analysis of polypropylene?

16 A. No, ma'am.

17 Q. Have you ever reported to anyone that
18 you have seen or observed any particle loss from
19 polypropylene?

20 A. Except to the patient, just to the
21 patient.

22 Q. Have you ever reported that to the FDA?

23 A. No, ma'am.

24 Q. Have you ever reported it to Ethicon?

25 A. No, ma'am.

1 A. Those two in specific, no. Just those
2 two being representative of the body of retropubic
3 and obturator TVTs.

4 MS. JONES: Let's just take a break and we'll
5 do that and have lunch, unless you all are all
6 assuming -- yes, it is one o'clock. You all are
7 ready for it.

8 MR. CARTMELL: Okay.

9 (WHEREUPON, a recess was had
10 from 12:58 to 1:38 p.m.)

11 BY MS. JONES:

12 Q. I'm going to quickly go through a series
13 of things just to clean up my notes to make sure
14 I've asked the question.

15 Other than Exhibit 6 which is your
16 PowerPoint, you never published anything on
17 polypropylene, is that correct?

18 A. That is correct.

19 Q. You never published anything on the
20 degradation of polypropylene, is that correct?

21 A. That is correct.

22 Q. You've never done -- never published
23 anything about the porosity of mesh, correct?

24 A. That is correct.

25 Q. You never published anything on the

1 cytotoxicity of mesh, correct?

2 A. That is correct.

3 Q. You never published anything on fibrotic
4 bridging, correct?

5 A. That is correct.

6 Q. You never published anything on
7 contracture, correct?

8 A. That is correct.

9 Q. You are not a pathologist?

10 A. I have not done a residency program in
11 pathology. I am not boarded by the American
12 Pathological Association.

13 Q. You are not a polymer chemist?

14 A. That is correct.

15 Q. Not an organic chemist?

16 A. That is correct.

17 Q. Not a toxicologist?

18 A. That is correct.

19 Q. You've done no research and development
20 with respect to polypropylene?

21 A. That is correct.

22 Q. You've never done any examination of a
23 biomaterial to evaluate tensile strength, for
24 example?

25 A. A biomaterial, we did a study on -- on

1 Q. And that information that you've
2 presented based upon your findings at that time, to
3 the extent that it was based upon any confidential
4 documents would have been based upon either Bard or
5 AMS documents, correct?

6 A. That was not related to any confidential
7 documents.

8 Q. So there wasn't any confidentiality
9 associated then with it, was there?

10 A. Well, from -- quite frankly, I err on
11 the side of I don't know what I can or can't talk
12 about in this and I prefer not to talk about it so
13 that I don't have any problems later on.

14 Q. Fair enough.

15 A. Okay.

16 Q. I'm going to skip around a little bit,
17 so just bear with me to get through with some of
18 this stuff.

19 You've never performed any pathological
20 testing on sutures, is that correct?

21 A. I did a pathology rotation when I was a
22 student and also during residency. We might have
23 looked at sutures under the microscope. But are
24 you talking about doing any kind of pathological
25 stuff?

1 Q. Analysis or study or --

2 A. No.

3 Q. And the same would be true with respect
4 to mesh or polypropylene in general?

5 A. That is correct.

6 Q. You've never dried or cleaned mesh for
7 any pathological analysis, correct?

8 A. That is correct.

9 Q. You have never sputter coated an
10 explanted mesh?

11 A. Have I explanted mesh, yes, I have.

12 Q. No. Have you sputter coated?

13 A. Sputter coated.

14 MR. CARTMELL: It sounds funny.

15 BY THE WITNESS:

16 A. I have explanted mesh. I really do not
17 remember ever sputter coating the explanted mesh.

18 BY MS. JONES:

19 Q. Have you ever done any differential
20 scanning calorimetry?

21 A. I don't even think I can pronounce that.

22 Q. Huh?

23 A. No, I have not.

24 Q. How about thermogravimetric analysis?

25 A. No.

1 Q. How about compliance testing to
2 determine mesh density?

3 A. No.

4 Q. How about any type of oxidative
5 degradation testing?

6 A. No.

7 Q. Any type of molecular weight
8 determination?

9 A. No.

10 Q. Any type of uniaxial testing?

11 A. Uniaxial tension testing?

12 Q. Testing.

13 A. Uniaxial would be a tensioning test?

14 Q. Yes.

15 A. Okay. No.

16 Q. Pore size measurement either with or
17 without load?

18 A. No.

19 Q. Mechanical testing?

20 A. No.

21 Q. Chemical analysis?

22 A. Of what?

23 Q. Of either polypropylene mesh or poly --

24 A. Oh, okay. I mean, I've done a lot of
25 chemical analysis back when I was in chemistry, but

1 not of mesh.

2 Q. Not of mesh, not of polypropylene?

3 A. That is correct.

4 Q. No toxicity or cytotoxicity testing of
5 polypropylene or mesh?

6 A. That is correct.

7 Q. Have you ever read the FDA regulations
8 pertaining to polypropylene meshes?

9 A. The FDA regulations regarding what?

10 Q. Polypropylene meshes?

11 A. Regarding what?

12 Q. Anything.

13 A. The -- quite frankly, that is such a
14 broad question, I don't know how to answer that
15 question.

16 Q. Well, when is the last time you reviewed
17 the FDA regulations on medical devices?

18 A. For what?

19 Q. Just for any purpose.

20 A. No, no, I mean for clearing devices, for
21 the various, you know, components of the device,
22 like the IFU? That's why I'm having a little bit
23 of problems.

24 Q. What I'm trying to find out is to what
25 extent you are going to claim that you are an

1 you would, why it is that you as a surgeon who
2 performs pelvic surgery has expertise related to
3 what warnings and adverse reactions need to be in
4 an IFU?

5 A. Well, I have experience using medical
6 devices, I have experience determining whether or
7 not I'm going to use medical devices in my
8 practice, I have experience determining if a
9 particular medical device is useful for a specific
10 patient and then counseling the patient on those
11 individual -- on the risks associated with a
12 particular medical device so that that patient can
13 determine if she wants to have a medical device
14 either implanted or used to treat her condition.

15 MR. CARTMELL: All right. Thanks. That's all
16 I have.

17 FURTHER EXAMINATION

18 BY MS. JONES:

19 Q. Doctor, you would agree that any other
20 urogynecologist or specialist in female pelvic
21 surgery or treating stress urinary incontinence
22 would have similar expertise, correct?

23 MR. CARTMELL: Object to the form.

24 BY THE WITNESS:

25 A. I think that doctors have -- that are

1 using the IFU, using it to decide if they are going
2 to keep it in their -- use a device in their
3 practice to determine if an individual patient that
4 device is useful for and then counseling the
5 patient on the use of that device, the risks and
6 benefits associated with it, I would say that that
7 would qualify them as an expert in IFUs.

8 MS. JONES: Thank you. That's all I have.

9 (Time Noted: 4:43 p.m.)

10 FURTHER DEPONENT SAITH NAUGHT.

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25